Bio-Rad develops antidaratumumab antibodies for drug monitoring

By Andre Rickard, The Science Advisory Board contributing writer

February 15, 2022 -- Bio-Rad Laboratories has launched a range of antidaratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars, according to the company.

Daratumumab is an anticancer drug that binds to the CD38 protein overexpressed in multiple myeloma cells, leading to immune-mediated apoptosis of the tumor cell. The new range of antidaratumumab antibodies comprises three fully human immunoglobulin G1 inhibitory antibodies with varying levels of affinity. The antibodies are ideal for use as surrogate positive controls in antidrug antibody assays and for the development of pharmacokinetic bridging enzyme-linked immunosorbent assays to measure the free drug, Bio-Rad said.

Bio-Rad offers a portfolio of recombinant, monoclonal, nonanimal-derived, anti-idiotypic antibodies and drug-target complex binders for the development of highly selective and sensitive assays. These reagents enable researchers to develop robust methods in a short timescale and produce translatable and reproducible results. The antibodies are generated using Human Combinatorial Antibody Libraries and CysDisplay, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents.

The antidaratumumab antibodies are approved for in vitro research purposes and for commercial applications providing in vitro testing services to support preclinical and clinical drug development.

10x Genomics inks license deal with Bio-Rad
10x Genomics and Bio-Rad Laboratories have settled their legal dispute and signed a global settlement and cross-license agreement.
Bio-Rad launches new StarBright dyes for flow cytometry
Bio-Rad Laboratories has unveiled three new StarBright dyes geared toward flow cytometry applications.
Bio-Rad wins appeal in 10x Genomics patent infringement ruling
Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed...
Bio-Rad acquires single-cell analysis company
Bio-Rad Laboratories has acquired Celsee, a company that offers instruments and consumables for single-cell analysis.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter